# EDGAR Filing Document

**Accession Number:** 0001503274
**File Stem:** 0001628280-25-053420
**Filing Date:** 2025-11
**Character Count:** 21406
**Document Hash:** fe2d48c278e61c55e5ffbee7aa941df8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-053420.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0001628280-25-053420

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20251120

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251120

**DATE AS OF CHANGE**: 20251120

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quanterix Corp
- **CENTRAL INDEX KEY:** 0001503274
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 208957988
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38319
- **FILM NUMBER:** 251503975

**BUSINESS ADDRESS:**
- **STREET 1:** 900 MIDDLESEX TURNPIKE
- **CITY:** BILLERICA
- **STATE:** MA
- **ZIP:** 01821
- **BUSINESS PHONE:** 617-301-9400

**MAIL ADDRESS:**
- **STREET 1:** 900 MIDDLESEX TURNPIKE
- **CITY:** BILLERICA
- **STATE:** MA
- **ZIP:** 01821

?xml version='1.0' encoding='ASCII'? qtrx-20251120

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

______________________________________

**FORM 8-K**

______________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 20, 2025**

_________________________________________________

**QUANTERIX CORPORATION**

(Exact name of registrant as specified in its charter)

_________________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38319** | **20-8957988** |
| (State or other jurisdiction<br>of incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **900 Middlesex Turnpike** | |
| **Billerica, MA** | **01821** |
| (Address of principal executive offices) | (Zip Code) |

---

**(617) 301-9400**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class:** | **Trading symbol(s):** | **Name of each exchange on which**<br>**registered:** |
| Common Stock, $0.001 par value per share | QTRX | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 5.02&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(b) On November 20, 2025, Paul Meister and David Walt, Ph.D. notified Quanterix Corporation (the "Company") of their retirement from the Board of Directors of the Company (the "Board") and each committee of the Board on which they served, effective immediately. Their decision to resign was not because of any disagreement with the Company on any matter relating to its operations, policies or practices.

(d) On November 20, 2025, the Board appointed Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D. to serve on the Board, effective immediately. Dr. Sachs will serve as a Class I director with a term that will expire at the Company's 2027 annual meeting of stockholders, and Dr. Hampton will serve as a Class II director with a term that will expire at the Company's 2028 annual meeting of stockholders. Dr. Hampton will be a member of the Audit Committee and Compensation Committee, and Dr. Sachs will be a member of the Compensation Committee of the Board.

There is no arrangement or understanding between Dr. Sachs or Dr. Hampton and any other person pursuant to which they were selected as directors of the Company, and there is no family relationship between either Dr. Sachs or Dr. Hampton and any of the Company's other directors or executive officers. Neither Dr. Sachs nor Dr. Hampton has any material interest in any transaction that is required to be disclosed under Item 404(a) of Regulation S-K.

Dr. Hampton and Dr. Sachs will be entitled to receive an annual cash retainer of $50,000 for their service on the Board, in accordance with the Company's policy for compensation of non-employee directors, as well as additional cash retainers in respect of committee service. Upon their appointment to the Board, they each will receive an initial grant of restricted stock units ("RSUs") with respect to a number of shares of the Company's common stock equivalent to 0.1% of the shares of Company common stock outstanding on the date of grant, which RSUs will vest in three equal installments on the first, second, and third anniversaries of the grant date. Thereafter they will be entitled to an annual grant of RSUs covering a number of shares of the Company's common stock equivalent to 0.05% of the outstanding shares as of the date of grant. The annual RSU award vests in full on the first anniversary of the grant date.

**Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD** 

On November 20, 2025, the Company issued a press release announcing certain Board and leadership changes, including the matters discussed in Item 5.02 of this current report. A copy of the Company's press release dated November 20, 2025 is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This information (including Exhibit 99.1) is being furnished under Item 7.01 of this Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 ("Exchange Act") or otherwise subject to the liabilities of that section, and such information shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

(d)Exhibits

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 99.1 | <u>[Press Release dated](ex991-qtrxx20251120.htm)[November](ex991-qtrxx20251120.htm)[20](ex991-qtrxx20251120.htm)[, 2025](ex991-qtrxx20251120.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: November 20, 2025 | **QUANTERIX CORPORATION** | **QUANTERIX CORPORATION** |
|  | **By:** | /s/ Vandana Sriram |
|  | **Name:** | Vandana Sriram |
|  | **Title:** | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth**

*Appoints Garret Hampton and Alan Sachs to the Board*

*Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director*

**BILLERICA, Mass. – November 20, 2025 –** Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately.

Dr. Hampton most recently served as President, Clinical Next Generation Sequencing and Oncology at Thermo Fisher Scientific. Dr. Sachs is the former Chief Medical Officer and Chief Scientific Officer of Thermo Fisher Scientific.

The Company also announced that Bill Donnelly, previously the non-Executive Chair of the Board, has been appointed Executive Chair, and Jeffrey Elliott, a current member of the Board, has been appointed to the newly created role of Lead Independent Director.

As Executive Chair, Mr. Donnelly will work closely with the Company's leadership team and provide support in select strategic and operational areas. This structure enables Chief Executive Officer Masoud Toloue to continue advancing the Company's key strategic initiatives, including expanding its blood- and tissue-based biomarker menu, launching LucentAD Complete™ for Alzheimer's diagnosis, and accelerating growth synergies from the Akoya acquisition.

Additionally, Paul Meister and David Walt, Ph.D. are stepping down from the Board after many years of service, effective immediately.

With these changes, the Quanterix Board now comprises nine members, seven of whom are independent.

"On behalf of the Company, I am pleased to welcome Garret and Alan to the Board." said Bill Donnelly, Executive Chair of the Board. "Their deep expertise in diagnostics, life sciences and product innovation will bring valuable perspectives to the Board. As we move beyond the integration stage and shift our focus toward growth, their combination of scientific insight, market knowledge, and experience in identifying and executing on growth opportunities will be invaluable."

Mr. Donnelly added, "I would also like to thank Paul and David for their years of service and dedication to Quanterix. As our founding scientist and a pioneer in precision medicine, David has helped revolutionize the way pathologists detect and treat disease, while Paul, as a leading life sciences investor, has provided countless insights and contributions to our strategy. Both Paul and David have been instrumental in the Company's growth, and we are deeply appreciative of the steady oversight and guidance they provided during their tenures. We wish them all the best."

"I am excited to work with Garret and Alan who bring exceptional technical knowledge and business leadership to our Board," said Masoud Toloue, CEO of Quanterix. "Bill's expanded role will further strengthen our operational alignment and help accelerate the achievement of our growth initiatives.

------

Together, these changes position the Company for continued leadership in the tools and diagnostics sector, advancing our mission to improve health outcomes for patients worldwide."

"I look forward to working closely with Masoud and the rest of the leadership team at Quanterix to advance our strategic priorities," added Mr. Donnelly. "With the acquisition of Akoya Biosciences now complete and the integration efforts advancing well, Quanterix is entering a new era. The Board and I are confident in the Company's ability to deliver meaningful value in the coming years for our shareholders and for patients, partners, and other stakeholders."

**About Garret Hampton, Ph.D.**

Garret Hampton has more than 35 years of experience across life sciences, diagnostics, and oncology. From 2020 to 2024, he served as President of Clinical Next Generation Sequencing and Oncology at Thermo Fisher Scientific, Inc. (NYSE: TMO), where he led a 800-person division focused on oncology diagnostics. Prior to that, he was Senior Vice President of Clinical Genomics at Illumina, Inc. (NASDAQ: ILMN), and previously held senior leadership roles at Genentech, Celgene and the Genomics Institute of the Novartis Research Foundation. He currently serves as an independent director of IDEAYA Biosciences, Inc. (NASDAQ: IDYA). Dr. Hampton earned his Ph.D. in Genetics from University College London and his M.A. and B.S. Natural Science, Genetics, from Trinity College Dublin.

**About Alan Sachs, M.D., Ph.D.**

Alan Sachs has more than two decades of experience in molecular diagnostics and technology development. Most recently, he spent nine years at Thermo Fisher Scientific (NYSE: TMO), serving as Chief Medical Officer from 2021 to 2025 and Chief Scientific Officer from 2016 to 2021. In those roles, he led the company's research and development efforts, championing innovation across disciplines and accelerating the adoption of diagnostic platforms and tests. Prior to that, he served as Vice President and Global Head of Research and Development at Life Technologies Corporation (formerly NASDAQ: LIFE), from 2012 to 2016. Earlier in his career, he spent a decade at Merck Research Laboratories from 2001 to 2011, where he ran technology development and application, built and led global departments in RNA therapeutics, molecular profiling and translational sciences, and managed complex external collaborations. He began his career as a faculty member at The University of California, Berkeley, where he contributed to the advancement of molecular and cellular biology. Dr. Sachs holds an M.D. and a Ph.D. in Cell Biology from Stanford University and a B.A. in Biological Sciences from Cornell University.

**About William Donnelly**

Bill Donnelly has served as a member of the Quanterix Board since August 2023 and has served as Chair since March 2025. Mr. Donnelly has more than 30 years of leadership experience in the life sciences and industrial technology sectors. He spent most of his career at Mettler-Toledo International Inc. (NYSE: MTD). Prior to his retirement in 2018 after more than 20 years with the company, he served as Executive Vice President responsible for finance, investor relations, supply chain and information technology. He joined Mettler-Toledo in 1997 as its Chief Financial Officer. Mr. Donnelly has been a director of Ingersoll Rand Inc. (NYSE: IR) since May 2017 and was appointed Lead Independent Director in November 2021. He has also served as a director of T. Rowe Price Group, Inc. (NASDAQ: TROW) since 2023. Mr. Donnelly holds a bachelor's degree in business administration from John Carroll University.

------

**About Jeffrey Elliott** 

Jeff Elliott has served as a member of the Quanterix Board since August 2024. Mr. Elliott has more than 20 years of experience in the diagnostics and life sciences industries, with deep expertise in finance, strategy and operations. Since September 2024, Mr. Elliott has served as a consultant to The Boston Consulting Group, Inc. From November 2016 to May 2024, he served as Chief Financial Officer of Exact Sciences Corporation (NASDAQ: EXAS) and as Chief Operating Officer from 2021 to 2023. Prior to his appointment as CFO, he served as Vice President of Strategy and Business Development at Exact Sciences. Earlier in his career, Mr. Elliott was a senior equity research analyst at Robert W. Baird & Co., where he covered healthcare companies in the diagnostics and life sciences tools sectors. Since March 2025, he has been a director of Sera Prognostics, Inc. (NASDAQ: SERA). Mr. Elliott earned a B.S. in Business Administration from the University of Illinois at Urbana-Champaign and an M.B.A. from the University of Chicago Booth School of Business. He is also a Chartered Financial Analyst (CFA) charter holder.

**About Quanterix**

Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.

**Cautionary Statement Regarding Forward-Looking Statements**

Statements included in this press release that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements about Quanterix's future business outlook, operations, strategy and financial performance. Words and phrases such as "may," "approximately," "continue," "should," "expects," "projects," "anticipates," "is likely," "look ahead," "look forward," "believes," "will," "intends," "estimates," "strategy," "plan," "could," "potential," "possible" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities with respect to Quanterix's future business, operations, strategy and financial performance: risks related to the impact of recent U.S. government policies, including reductions in federal research funding and increased tariffs; risks that we may not realize the expected benefits of our cost reduction actions; risks associated with the anticipated timing for launch of, and features of, Quanterix's next-generation instrument, Simoa One; risks that Quanterix may fail to realize the anticipated benefits and synergies of its recent acquisitions of Emission, Inc. and Akoya Biosciences, Inc.; the risk that integrating Quanterix's business with that of Akoya could be more difficult, costly or time-consuming than expected; risks that Quanterix's estimates regarding expenses, future revenues, capital requirements, and needs for additional

------

financing could be incorrect; risks related to the restatement of Quanterix's consolidated financial statements, including risks of increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions, or investigation; risks related to Quanterix's ability to maintain effective internal control over financial reporting and disclosure controls and procedures, including its ability to remediate existing material weaknesses in its internal control over financial reporting and the timing of any such remediation; risks related to defects or other quality issues in Quanterix's products that could lead to unforeseen costs, product recalls, adverse regulatory actions, negative publicity and litigation; risks related to Quanterix's ability to retain and expand its customer base and achieve sufficient market acceptance of its products; and other factors that may affect future results of Quanterix and the combined company. Additional factors that could cause results to differ materially from those described above can be found in the periodic reports filed by Quanterix with the SEC, including the "Risk Factors" sections contained therein, which are available on the SEC's website at www.sec.gov.

All forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix's underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix anticipates. Quanterix cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Quanterix does not assume any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.

**Investor Relations Contact:**

Joshua Young

(508) 846-3327

ir@quanterix.com

<br>